Rocket Pharma (RCKT) P/E multiplikatori

Rocket Pharmaceuticals Inc (RCKT) brendining ramzi va logotipi

Rocket Pharmaceuticals (RCKT) uchun ushbu narxlar grafigi yurak-qon tomir va qon patologiyalari uchun gen terapiyalarini ishlab chiqayotgan (KRESLADI) kompaniyaning faoliyatini aks ettiradi, bunda P/E koeffitsiyenti -15.70 darajasida turibdi. Biznes irsiy kasalliklar uchun zamonaviy davolash vositalarining yetishmasligi va ixtisoslashtirilgan klinikalar tomonidan yuqori qiziqishdan foydalanmoqda. Xatarlar genetik buzilishlarga chaling bolalarni davolashga qaratilgan keng qamrovli ishlanmalar portfeli orqali yumshatiladi.

RCKT Rocket Corp: Narx-foyda koeffitsiyenti 04.07.2022 - 12.11.2026 oraligʻida

Rocket Pharmaceuticals kompaniyasining tahliliy kesimlari

- aksiyalar qiymati va narxlar bo'yicha konsensus prognoz:
Aksiya kotirovkalari rocketpharma.com|RCKT - Maqsadli narxlar grafigi
- bozor kapitallashuvi tafsilotlari:
Bozor kapitallashuvi Rocket Pharmaceuticals, Inc.|RCKT - Korxona qiymati
- kompaniyaning balans qiymati tafsilotlari:
Bitta aksiya hisobiga sof aktivlar qiymati Rocket Pharmaceuticals|RCKT - Kompaniyaning sof aktivlari|Bozor kapitallashuvining balans qiymatiga multiplikatori rocketpharma.com|RCKT - Kompaniyaning yakuniy aktivlari
- qarzlar va to'lov qobiliyati haqida ma'lumot:
Barcha qarzlarning o‘z mablag‘lariga nisbati Rocket Pharmaceuticals|RCKT - Uzoq muddatli qarzning o'z kapitaliga nisbati|Qisqa muddatli majburiyatlarning o'z kapitaliga nisbati Rocket Corp|RCKT - Kompaniyaning jamlangan qarzlari|Qarzning sof aktivlarga nisbati Rocket Pharmaceuticals, Inc.|RCKT - Kompaniyaning uzoq muddatli qarzlari|Kompaniyaning qisqa muddatli qarzlari Rocket Pharmaceuticals|Oraliq qoplash koeffitsiyenti rocketpharma.com
- biznes foydasi va investitsiya koeffitsiyentlari ma'lumotlari:
RCKT - Kompaniyaning sof foydasi|Kelajakdagi foyda Rocket Pharmaceuticals|RCKT - P/E multiplikatori|Forvard P/E multiplikatori Rocket Pharma|RCKT - PEG multiplikatori|Korxona qiymatining foizlar, soliqlar va amortizatsiyadan oldingi foydaga nisbati koeffitsiyenti Rocket Pharmaceuticals, Inc.|RCKT - EBITDA operatsion foydasi|So'nggi o'n ikki oy davomida bitta aksiya uchun sof foyda Rocket Pharmaceuticals|RCKT - So'nggi 12 oy davomida bir aksiya uchun sof foyda|Choraklik EPS foyda o'sishi rocketpharma.com|RCKT - Bu yil bir aksiya uchun sof foyda o'sishi|Keyingi yilda bir aksiya uchun foydaning prognoz qilingan ortishi Rocket Pharmaceuticals
Kompaniyaning jamlanma tahlili:rocketpharma.com - RCKT
Rocket Pharma yetakchi tovari

P/E koeffitsiyenti biznesning bozor qiymatini uning haqiqiy moliyaviy natijasi bilan solishtirish orqali foydaning bir birlik xarajatini aks ettiradi. Rocket Pharmaceuticals (RCKT) uchun ushbu hisob-kitob gen terapiyasining tijoratlashtirish bosqichigacha bo'lgan yuqori klinik sinov xarajatlari tufayli murakkablashgan. Kompaniyaning P/E koeffitsiyentini tahlil qilish orqali investor birlik xarajatlarining oshishi baholashga qanday ta'sir ko'rsatayotganini ko'rishi mumkin. Uzoq muddatli konsensus koeffitsiyentni kelajakdagi savdo salohiyati bilan solishtirishni talab qiladi.

Muhim raqobatchilar

Narx-foyda koeffitsiyenti Tempus AI Inc (TEM)|Narxning foydaga nisbati Qiagen (QGEN)|P/E multiplikatori Ionis Pharmaceuticals, Inc. (IONS)|P/E multiplikatori RGEN (Repligen Corp.)|Avidity Corp (RNA) - Kapitalizatsiyaning foydaga nisbati|CRSP: Narx-foyda koeffitsiyenti|genedx.com - Bozor narxining sof foydaga nisbati|RARE (Ultragenyx) - Narx-foyda koeffitsiyenti|Beam Therapeutics Inc - Kompaniya qiymatining sof foydaga nisbati|Narxning foydaga nisbati Sarepta Therapeutics Inc|Twist Bioscience Corp - Kapitalizatsiyaning sof foydaga nisbati|P/E multiplikatori TXG|NTLA (intelliatx.com) - Kompaniya qiymatining sof foydaga nisbati|P/E multiplikatori STOK (Stoke Therapeutics, Inc.)|P/E multiplikatori BioLife Solutions Inc BLFS|WVE - Narxning foydaga nisbati|Kompaniya qiymatining sof foydaga nisbati MAZE (Maze Therapeutics Corp)|Sionna Therapeutics Inc (SION) - Narxning foydaga nisbati|Narx-foyda koeffitsiyenti primemedicine.com|TSHA (Taysha Gene Therapies, Inc.) - P/E multiplikatori|P/E multiplikatori uniQure NV|P/E multiplikatori MGTX|Narx-foyda koeffitsiyenti REGENXBIO Corp RGNX|P/E multiplikatori SLDB (Solid Biosciences Inc.)|ocugen.com (OCGN) - Kapitalizatsiyaning foydaga nisbati|PACB: Narx-foyda koeffitsiyenti|BNTC - P/E multiplikatori|DSGN (Design Pharma) - Narx-foyda koeffitsiyenti|FDMT: Bozor narxining sof foydaga nisbati|LXEO (Lexeo Therapeutics Inc.) - P/E multiplikatori|Korro Bio, Inc (KRRO) - Biznesning o‘zini qoplash muddati|P/E multiplikatori EDIT|Narx-foyda koeffitsiyenti Silence Therapeutics PLC SLN|P/E multiplikatori PRQR (ProQR Therapeutics)|P/E multiplikatori Codexis Inc CDXS|SGMO - Narxning foydaga nisbati|NAUT: Narxning foydaga nisbati|Metagenomi (MGX) - Narxning foydaga nisbati|DTIL - Biznesning o‘zini qoplash muddati|Narxning foydaga nisbati Generation Bio Co|BOLD: Kompaniya qiymatining sof foydaga nisbati|P/E multiplikatori XCUR|Narx-foyda koeffitsiyenti imunon.com IMNN|Narxning foydaga nisbati Phio Pharmaceuticals Corp. PHIO|P/E multiplikatori Mustang Bio Inc MBIO|RNAZ: Narx-foyda koeffitsiyenti|Bionano Genomics, Inc. - Bozor narxining sof foydaga nisbati|APDN: P/E multiplikatori|Narx-foyda multiplikatori BLUE|Narxning foydaga nisbati ImmunoPrecise Antibodies Ltd|Narx-foyda multiplikatori OMGA (Omega Therapeutics Inc)|P/E multiplikatori OMIC|P/E multiplikatori Regulus (RGLS)|Narxning foydaga nisbati Syros Pharmaceuticals SYRS|Kompaniya qiymatining sof foydaga nisbati TBIO|TCON - Narxning foydaga nisbati|Kapitalizatsiyaning foydaga nisbati Unity Biotechnology Inc.